The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...

Clinical trials are the cornerstone of drug innovation in modern medicine, providing a systematic, evidence-based framework for determining the efficacy and safety of treatments before they reach ...

Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...

Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise. Meanwhile, ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...